← 홈

Catalyst · Landscape

향후 6개월 내 primary completion 예정인 활성 임상과 큐레이션·승인 프로그램의 phase 분포입니다. CT.gov completion date 기반 추정이며 공식 readout 일정과 다를 수 있습니다. RSS

파이프라인 Phase 분포

큐레이션·FDA·임상 3건 이상 프로그램 2029개 — catalyst 일정과 별도의 전체 파이프라인 스냅샷입니다.

Preclinical
132
Phase 1
491
Phase 2
979
Phase 3
293
Approved
134

Catalyst target · modality

향후 6개월 catalyst 8건 · 타깃·모달리티 분포

ADC 2Antibody 6
Non-Small
2
Precursor
2
Nectin-4
2
Chronic
1
FRα
1

향후 6개월 Catalyst(8 / 80)

활성 recruiting/enrolling 임상 · CT.gov completion 기준 · 상위 80건 표시

완료 예정프로그램PhaseStatusEndpoint신뢰도NCT
2026년 9월RamucirumabAntibody · Non-Small Cell Lung CancerPhase 3RecruitingProgression Free Survival (PFS) in all randomized participants; Overall Survival (OS) for 3L+ participants신뢰 높음NCT06346392
2026년 9월BlinatumomabAntibody · Precursor Cell Lymphoblastic Leukemia-LyPhase 3Active, not recruitingDisease Free Survival (DFS) of High-risk (HR) and Intermediate-risk (IR) Relapse Patients; Disease Free Survival (DFS) of Low Risk (LR) Relapse Patients신뢰 높음NCT02101853
2026년 9월TocilizumabAntibody · Chronic Lymphocytic LeukemiaPhase 3Active, not recruitingmodified Rankin Scale (mRS) score at 90 days신뢰 높음NCT07263776
2026년 9월TalquetamabAntibody · FRα—RecruitingDescribe Baseline Characteristics of Participants with Relapsed/Refractory Multiple Myeloma (RRMM) who Received Teclistamab/ Talquetamab Outside of Clinical Trials; Overall Response Rate (ORR) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Time to First Response in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Time to Best Response in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Duration of Response (DOR) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Minimal Residue Assessment (MRD) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Overall Survival (OS) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Progression Free Survival (PFS) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Time to Next Treatment (TTNT) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Describe the Safety Management of Teclistamab/Talquetamab in the Treatment of Participants with RRMM Outside of Clinical Trials신뢰 높음NCT06285318
2026년 9월Padcev (enfortumab vedotin)ADC · Nectin-4N/ARecruitingChange from Baseline in Circulating EV Concentration신뢰 높음NCT07558447
2026년 9월RamucirumabAntibody · Non-Small Cell Lung CancerPhase 2RecruitingTo estimate overall response rate신뢰 높음NCT04332367
2026년 9월Padcev (enfortumab vedotin)ADC · Nectin-4Phase 2Active, not recruitingCohorts 1-8: Confirmed Overall Response Rate (ORR) (Complete Response [CR] and Partial Response [PR]) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (V)1.1 Per Investigator Assessment; Cohort 9: Confirmed ORR (CR and PR) Per RECIST V1.1 Per Investigator Assessment신뢰 높음NCT04225117
2026년 9월BlinatumomabAntibody · Precursor Cell Lymphoblastic Leukemia-LyPhase 2Not yet recruitingProgression free survival (PFS); 100 day adverse events (AE)신뢰 높음NCT06075238
  • 2026년 9월신뢰 높음
    Ramucirumab

    Antibody · Non-Small Cell Lung Cancer · Phase 3

    Progression Free Survival (PFS) in all randomized participants; Overall Survival (OS) for 3L+ participants

    NCT06346392
  • 2026년 9월신뢰 높음
    Blinatumomab

    Antibody · Precursor Cell Lymphoblastic Leukemia-Ly · Phase 3

    Disease Free Survival (DFS) of High-risk (HR) and Intermediate-risk (IR) Relapse Patients; Disease Free Survival (DFS) of Low Risk (LR) Relapse Patients

    NCT02101853
  • 2026년 9월신뢰 높음
    Tocilizumab

    Antibody · Chronic Lymphocytic Leukemia · Phase 3

    modified Rankin Scale (mRS) score at 90 days

    NCT07263776
  • 2026년 9월신뢰 높음
    Talquetamab

    Antibody · FRα · —

    Describe Baseline Characteristics of Participants with Relapsed/Refractory Multiple Myeloma (RRMM) who Received Teclistamab/ Talquetamab Outside of Clinical Trials; Overall Response Rate (ORR) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Time to First Response in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Time to Best Response in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Duration of Response (DOR) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Minimal Residue Assessment (MRD) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Overall Survival (OS) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Progression Free Survival (PFS) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Time to Next Treatment (TTNT) in Participants with RRMM who Received Teclistamab/Talquetamab Outside of Clinical Trials; Describe the Safety Management of Teclistamab/Talquetamab in the Treatment of Participants with RRMM Outside of Clinical Trials

    NCT06285318
  • 2026년 9월신뢰 높음
    Padcev (enfortumab vedotin)

    ADC · Nectin-4 · N/A

    Change from Baseline in Circulating EV Concentration

    NCT07558447
  • 2026년 9월신뢰 높음
    Ramucirumab

    Antibody · Non-Small Cell Lung Cancer · Phase 2

    To estimate overall response rate

    NCT04332367
  • 2026년 9월신뢰 높음
    Padcev (enfortumab vedotin)

    ADC · Nectin-4 · Phase 2

    Cohorts 1-8: Confirmed Overall Response Rate (ORR) (Complete Response [CR] and Partial Response [PR]) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (V)1.1 Per Investigator Assessment; Cohort 9: Confirmed ORR (CR and PR) Per RECIST V1.1 Per Investigator Assessment

    NCT04225117
  • 2026년 9월신뢰 높음
    Blinatumomab

    Antibody · Precursor Cell Lymphoblastic Leukemia-Ly · Phase 2

    Progression free survival (PFS); 100 day adverse events (AE)

    NCT06075238